Core Viewpoint - The report outlines the approval and details regarding the lifting of restrictions on shares of Jiangsu Hualan Pharmaceutical New Materials Co., Ltd. prior to its initial public offering (IPO) and the subsequent listing of these shares for trading [1][2]. Summary by Sections 1. Type of Restricted Shares - The company issued 33,666,667 shares during its IPO, with a total share capital of 134,666,667 shares post-IPO. Of these, 103,765,403 shares were subject to restrictions, representing 77.05% of the total. The current release involves 1,756,450 shares, accounting for 1.30% of the total share capital [1][2]. 2. Changes in Share Capital - Following the issuance of restricted shares, the total share capital increased to 135,786,667 shares after the granting of 1,120,000 restricted shares on March 16, 2023. The company also canceled 6,412,625 shares held in a repurchase account, leading to a total of 126,308,942 shares as of the report date [3][4]. 3. Commitments and Compliance - The controlling shareholder, Jiangyin Hualan Electromechanical Technology Co., Ltd., committed to not pledging or transferring shares for 36 months post-IPO. If the stock price falls below the IPO price for 20 consecutive trading days, the lock-up period is extended by 6 months. All commitments have been adhered to without any violations [5][6][9]. 4. Listing and Trading Arrangements - The shares will be available for trading starting May 15, 2025. A total of 37,827,846 shares will be released, which is 29.9487% of the total share capital. The release involves four shareholders, with no shares being pledged or frozen [10][12]. 5. Share Structure Post-Release - After the release of restricted shares, the structure will reflect 38,032,821 restricted shares (30.11%) and 126,103,967 unrestricted shares (99.84%). The total share capital remains at 126,308,942 shares [11][12]. 6. Sponsor's Verification Opinion - The sponsor confirms that all shareholders have complied with their lock-up commitments and that the application for the release of restricted shares meets all regulatory requirements. The information disclosed regarding the release is deemed accurate and complete [13].
华兰股份: 华泰联合证券有限责任公司关于江苏华兰药用新材料股份有限公司首次公开发行前已发行股份部分解除限售并上市流通的核查意见